Close
Nordic 9Nordic 9

PAACS Invest (investor - Others)

Norway
See something wrong or missing? Let us know

PAACS Invest AS is an family office firm of Stromme family (Masha Stromme and Dag Stromme) from Norway that primarily focuses on active investments in healthcare and technology.

Average round investment:N/A USD
Average number per year:0.0
Distribution: 2021 (1)
Portfolio companies: Norway Hemispherian
Mostly invests in: Norway Norway (1) Biotech (1)

1 tracked investments in:

You need an account to access this feature. Log in or create one from here.

Do you have a question? Talk to us.

Investors with similar profile to PAACS Invest

Name Criteria
Norway Ventac Partners
66%
  • Range for average deal size: n/a USD
  • Similar verticals: Biotech, Health services
  • Similar business models: B2B
  • Common investees countries: Norway
Finland DevCo Partners
63%
  • Range for average deal size: n/a USD
  • Similar verticals: Biotech, Health services
  • Similar business models: B2B
IDO Investments
63%
  • Range for average deal size: n/a USD
  • Similar verticals: Biotech, Health services
  • Similar business models: B2B
Sweden Mertiva
63%
  • Range for average deal size: n/a USD
  • Similar verticals: Biotech, Health services
  • Similar business models: B2B
Spain Plastigaur
63%
  • Range for average deal size: n/a USD
  • Similar verticals: Biotech, Health services
  • Similar business models: B2B
Xeraya Capital
63%
  • Range for average deal size: n/a USD
  • Similar verticals: Biotech, Health services
  • Similar business models: B2B
United States Magnet Ventures
63%
  • Range for average deal size: n/a USD
  • Similar verticals: Biotech, Health services
  • Similar business models: B2B
Switzerland SNGLR Capital
63%
  • Range for average deal size: n/a USD
  • Similar verticals: Biotech, Health services
  • Similar business models: B2B
Denmark Noon Ventures
63%
  • Range for average deal size: n/a USD
  • Similar verticals: Biotech, Health services
  • Similar business models: B2B
United States Decheng Capital
63%
  • Range for average deal size: n/a USD
  • Similar verticals: Biotech, Health services
  • Similar business models: B2B
Top